Zomedica Pharmaceuticals (CVE:ZOM) Hits New 52-Week Low at $0.33

Zomedica Pharmaceuticals Corp (CVE:ZOM)’s share price reached a new 52-week low on Wednesday . The stock traded as low as C$0.33 and last traded at C$0.33, with a volume of 5000 shares changing hands. The stock had previously closed at C$0.43.

Separately, HC Wainwright reiterated a “buy” rating on shares of Zomedica Pharmaceuticals in a report on Wednesday, June 5th.

The firm has a market cap of $46.46 million and a PE ratio of -1.52.



Zomedica Pharmaceuticals (CVE:ZOM) last announced its quarterly earnings results on Friday, May 10th. The company reported C($0.16) earnings per share (EPS) for the quarter.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://dakotafinancialnews.com/2019/06/12/zomedica-pharmaceuticals-cvezom-hits-new-52-week-low-at-0-33.html.

About Zomedica Pharmaceuticals (CVE:ZOM)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies.

Further Reading: Diversification

Receive News & Ratings for Zomedica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.